Trial Profile
An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2018
Price :
$35
*
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms Epitome2ext
- Sponsors Actelion Pharmaceuticals
- 14 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinilcaTrials.gov record.
- 09 Apr 2015 Planned End Date changed from 1 Apr 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov
- 09 Apr 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov